Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Clinical and Preclinical Characterisation Of The Metabolites Of The BCR-ABL Tyrosine Kinase Inhibitor Nilotinib

Paul W. Manley, Ph. D., Jürgen Mestan, Ph D, Jennifer Sheng, Ph D, Phi Tran, M Sc, Mark Kagan, Ph D

Blood (2013) 122 (21): 4011.

https://doi.org/10.1182/blood.V122.21.4011.4011

Published: 2013

Journal Articles

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Arghya Ray, Sandra W. Cowan-Jacob, Paul W. Manley, Jürgen Mestan, James D. Griffin

Blood (2007) 109 (11): 5011–5015.

https://doi.org/10.1182/blood-2006-01-015347

Published: 2007

Includes: Supplemental data

Journal Articles

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

Nikolas von Bubnoff, Paul W. Manley, Jurgen Mestan, Jana Sanger, Christian Peschel, Justus Duyster

Blood (2006) 108 (4): 1328–1333.

https://doi.org/10.1182/blood-2005-12-010132

Published: 2006

Journal Articles

Identification of Bcr/Abl Point Mutations Conferring Resistance to the Abl Kinase Inhibitor AMN107 by a Random Mutagenesis Study.

Arghya Ray, PhD, Sandra Cowan-Jacob, PhD, Paul W. Manley, PhD, Jurgen Mestan, PhD, James D. Griffin, MD

Blood (2005) 106 (11): 494.

https://doi.org/10.1182/blood.V106.11.494.494

Published: 2005

Journal Articles

AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.

James D. Griffin, MD, Doriano Fabbro, PhD, Gabriele Fendrich, PhD, Brian Huntly, MD, PhD, Sandra Jacob, PhD, Andrew Kung, MD, PhD, Jurgen Mestan, PhD, Ellen Weisberg, PhD, D. Gary Gilliland, MD, PhD, Paul W. Manley, PhD

Blood (2004) 104 (11): 551.

https://doi.org/10.1182/blood.V104.11.551.551

Published: 2004

NARROW

Clinical and Preclinical Characterisation Of The Metabolites Of The BCR-ABL Tyrosine Kinase Inhibitor Nilotinib

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

Identification of Bcr/Abl Point Mutations Conferring Resistance to the Abl Kinase Inhibitor AMN107 by a Random Mutagenesis Study.

AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.

Email alerts

ASH Publications

American Society of Hematology

Clinical and Preclinical Characterisation Of The Metabolites Of The BCR-ABL Tyrosine Kinase Inhibitor Nilotinib

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

Identification of Bcr/Abl Point Mutations Conferring Resistance to the Abl Kinase Inhibitor AMN107 by a Random Mutagenesis Study.

AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only